The United Kingdom and the United States have concluded a landmark trade agreement that will ensure zero levies on British pharmaceutical shipments being sold in the American market.
Key Provisions of the Pact
In exchange for the tariff guarantee, the UK has pledged to boost funding on pharmaceuticals through the NHS. This move secures that import taxes on these crucial products will be held at nothing for a timeframe of the next three years.
This deal follows recent threats to hike import taxes on branded drug imports, with increases discussed reaching double the cost.
"This agreement with the UK reinforces the global environment for new treatments and introduces much-needed balance to transatlantic medicine commerce," an announcement declared.
Commercial Importance
Drugs constitute one of the Britain's biggest exports to the US, which is clearly the biggest destination for major UK drugmakers.
Statistics indicate that in the one-year period to the end of last September, the UK sold drugs worth over eleven billion pounds to the US. This figure represented nearly one-fifth of British export trade in that span.
"This deal secures jobs, boosts investment and facilitates the UK to establish itself as a worldwide center for medical research," a minister stated.
Detailed UK Commitments
The pact includes several key changes from the British government:
- Price Threshold Increase: The UK will increase the price threshold at which it judges new therapies to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a aim to double overall NHS spending on treatments from 0.3 percent of GDP to 0.6% over the coming ten years.
- Rebate Cap: The percentage drug companies must return to the NHS to control costs will be limited at fifteen percent. Last year, refunds exceeded twenty percent.
Recent Tensions
The pact comes amid a ongoing dispute between the sector and the UK government over spending levels and approval rates.
The disagreement were exacerbated by assertions that American customers were charged several times more for the equivalent treatments than people in the UK and Europe.
Recently, several major pharmaceutical investments in the UK have been halted or scrapped, while substantial investments have been pledged toward projects in the United States.
The Science Minister acknowledged that the NHS had to invest a greater share on medicines, noting that its budget allocation on drugs had shrunk as a proportion of its overall budget over the past decade.
